147 related articles for article (PubMed ID: 11727933)
1. pH and multidrug resistance.
Roepe PD
Novartis Found Symp; 2001; 240():232-47; discussion 247-50, 265-8. PubMed ID: 11727933
[TBL] [Abstract][Full Text] [Related]
2. Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?
Hoffman MM; Wei LY; Roepe PD
J Gen Physiol; 1996 Oct; 108(4):295-313. PubMed ID: 8894978
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
4. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
5. In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.
Chen Y; Simon SM
J Cell Biol; 2000 Mar; 148(5):863-70. PubMed ID: 10704438
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells.
Ouar Z; Lacave R; Bens M; Vandewalle A
Cell Biol Toxicol; 1999 Apr; 15(2):91-100. PubMed ID: 10408356
[TBL] [Abstract][Full Text] [Related]
7. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Ruth A; Stein WD; Rose E; Roninson IB
Biochemistry; 2001 Apr; 40(14):4332-9. PubMed ID: 11284689
[TBL] [Abstract][Full Text] [Related]
8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
10. Biophysical aspects of P-glycoprotein-mediated multidrug resistance.
Wadkins RM; Roepe PD
Int Rev Cytol; 1997; 171():121-65. PubMed ID: 9066127
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance through the spectacle of P-glycoprotein.
Goda K; Bacsó Z; Szabó G
Curr Cancer Drug Targets; 2009 May; 9(3):281-97. PubMed ID: 19442049
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of P-glycoprotein in relation to passive membrane permeation.
Eytan GD; Kuchel PW
Int Rev Cytol; 1999; 190():175-250. PubMed ID: 10331240
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance proteins and other drug transport-related resistance to natural product agents.
Broxterman HJ; Giaccone G; Lankelma J
Curr Opin Oncol; 1995 Nov; 7(6):532-40. PubMed ID: 8547402
[TBL] [Abstract][Full Text] [Related]
15. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs.
Raghunand N; Martínez-Zaguilán R; Wright SH; Gillies RJ
Biochem Pharmacol; 1999 May; 57(9):1047-58. PubMed ID: 10796075
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
17. Visualization of multidrug resistance in vivo.
Hendrikse NH; Franssen EJ; van der Graaf WT; Vaalburg W; de Vries EG
Eur J Nucl Med; 1999 Mar; 26(3):283-93. PubMed ID: 10079321
[TBL] [Abstract][Full Text] [Related]
18. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1).
Sharom FJ
Biochem Cell Biol; 2006 Dec; 84(6):979-92. PubMed ID: 17215884
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system.
Ramachandra M; Ambudkar SV; Gottesman MM; Pastan I; Hrycyna CA
Mol Biol Cell; 1996 Oct; 7(10):1485-98. PubMed ID: 8898356
[TBL] [Abstract][Full Text] [Related]
20. The role of MDR-1 in refractory lymphoma.
Sandor V; Wilson W; Fojo T; Bates SE
Leuk Lymphoma; 1997 Dec; 28(1-2):23-31. PubMed ID: 9498700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
